---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-23-000018"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T07:56:52.629762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma reports Q1 2023 net sales $716.6M, adjusted EPS $1.98; raises full-year guidance

## Summary
- Net sales $716.6M (down 0.5% YoY); organic sales growth 2.3%. Reported diluted EPS $1.85 (down 19.2%); adjusted diluted EPS $1.98 (down 13.9%).
- Raised FY2023 net sales guidance to $2.965-2.990B from $2.935-2.960B; adjusted EPS guidance to $7.50-7.65 from $7.25-7.40.
- Proprietary Products segment net sales $583.1M (down 3.0%); Biologics market unit organic sales declined double-digits due to lower COVID-19 sales.
- Operating cash flow $138.1M; free cash flow $56.0M (down 34.4%). Repurchased 183,360 shares for $60.1M at avg price $327.90.
- Board approved Q3 2023 dividend $0.19/share payable Aug 2, 2023 to holders of record Jul 26, 2023.

## SEC filing metadata
- accession: 0000105770-23-000018
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/0000105770-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/wst-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-23-000018
- JSON: https://secwatch.observer/filing/0000105770-23-000018.json
- Plain text: https://secwatch.observer/filing/0000105770-23-000018.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2023 results: revenue $716.6 million, EPS $1.85. Guidance raised.
  - Period: first-quarter 2023
  - Revenue: $716.6 million
  - EPS: $1.85
  - Guidance: raised
  - Result: reported results
  source text: West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2023 and updated full-year 2023 financial guidance. First-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $716.6 million declined 0.5%; organic sales growth was 2.3%. • Reported-diluted EPS of $1.85 declined by 19.2%. • Adjusted-diluted EPS of $1.98 declined by 13.9%. • The Company is updating full-year 2023 financial guidance of net sales to a new range of $2.965 billion to $2.990 billion compared to a prior range of $2.935 billion to $2.960 billion. • The Company is updating full-year 2023 financial guidance of adjusted-diluted EPS to a new range of $7.50 to $7.65, compared to a prior range of $7.25 to $7.40.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/0000105770-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.